Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 656

1.

Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis.

Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST.

Cancer Res. 2008 May 15;68(10):3655-61. doi: 10.1158/0008-5472.CAN-07-2940.

2.

WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer.

Zeilstra J, Joosten SP, Wensveen FM, Dessing MC, Schütze DM, Eldering E, Spaargaren M, Pals ST.

Biochem Biophys Res Commun. 2011 Mar 4;406(1):1-6. doi: 10.1016/j.bbrc.2010.12.070. Epub 2010 Dec 22.

PMID:
21184732
3.

Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway.

Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST.

Am J Pathol. 1999 Feb;154(2):515-23.

4.

APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.

Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, Louvard D, Fodde R, Robine S.

Gastroenterology. 2006 Oct;131(4):1096-109. Epub 2006 Aug 16. Erratum in: Gastroenterology. 2006 Dec;131(6):2029.

PMID:
17030180
5.

Elevated Dnmt3a activity promotes polyposis in Apc(Min) mice by relaxing extracellular restraints on Wnt signaling.

Samuel MS, Suzuki H, Buchert M, Putoczki TL, Tebbutt NC, Lundgren-May T, Christou A, Inglese M, Toyota M, Heath JK, Ward RL, Waring PM, Ernst M.

Gastroenterology. 2009 Sep;137(3):902-13, 913.e1-11. doi: 10.1053/j.gastro.2009.05.042. Epub 2009 May 18.

PMID:
19454286
6.

Phases of canonical Wnt signaling during the development of mouse intestinal epithelium.

Kim BM, Mao J, Taketo MM, Shivdasani RA.

Gastroenterology. 2007 Aug;133(2):529-38. Epub 2007 May 3.

PMID:
17681174
7.

Inhibition of intestinal polyposis with reduced angiogenesis in ApcMin/+ mice due to decreases in c-Myc expression.

Yekkala K, Baudino TA.

Mol Cancer Res. 2007 Dec;5(12):1296-303. doi: 10.1158/1541-7786.MCR-07-0232. Erratum in: Mol Cancer Res. 2008 Feb;6(2):340.

8.

Cooperation between the thyroid hormone receptor TRalpha1 and the WNT pathway in the induction of intestinal tumorigenesis.

Kress E, Skah S, Sirakov M, Nadjar J, Gadot N, Scoazec JY, Samarut J, Plateroti M.

Gastroenterology. 2010 May;138(5):1863-74. doi: 10.1053/j.gastro.2010.01.041. Epub 2010 Jan 28.

PMID:
20114049
9.

Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon.

Paulsen JE, Steffensen IL, Løberg EM, Husøy T, Namork E, Alexander J.

Cancer Res. 2001 Jul 1;61(13):5010-5.

10.

MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis.

Reitmair AH, Cai JC, Bjerknes M, Redston M, Cheng H, Pind MT, Hay K, Mitri A, Bapat BV, Mak TW, Gallinger S.

Cancer Res. 1996 Jul 1;56(13):2922-6.

11.

BCL9-2 promotes early stages of intestinal tumor progression.

Brembeck FH, Wiese M, Zatula N, Grigoryan T, Dai Y, Fritzmann J, Birchmeier W.

Gastroenterology. 2011 Oct;141(4):1359-70, 1370.e1-3. doi: 10.1053/j.gastro.2011.06.039. Epub 2011 Jun 23.

PMID:
21703997
12.

Intestinal epithelial cell-specific CD98 expression regulates tumorigenesis in Apc(Min/+) mice.

Nguyen HT, Dalmasso G, Yan Y, Laroui H, Charania M, Ingersoll S, Ayyadurai S, Zhang Y, Sitaraman S, Merlin D.

Lab Invest. 2012 Aug;92(8):1203-12. doi: 10.1038/labinvest.2012.83. Epub 2012 May 28.

13.

Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.

Zagani R, Hamzaoui N, Cacheux W, de Reyniès A, Terris B, Chaussade S, Romagnolo B, Perret C, Lamarque D.

Gastroenterology. 2009 Oct;137(4):1358-66.e1-3. doi: 10.1053/j.gastro.2009.06.039. Epub 2009 Jun 21.

PMID:
19549529
14.

The Intestinal Wnt/TCF Signature.

Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G, Clevers H.

Gastroenterology. 2007 Feb;132(2):628-32. Epub 2006 Aug 18.

PMID:
17320548
15.

Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse.

Ignatenko NA, Holubec H, Besselsen DG, Blohm-Mangone KA, Padilla-Torres JL, Nagle RB, de Alboránç IM, Guillen-R JM, Gerner EW.

Cancer Biol Ther. 2006 Dec;5(12):1658-64. Epub 2006 Dec 7.

PMID:
17106247
16.

Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APCMin/+ mouse.

Paoni NF, Feldman MW, Gutierrez LS, Ploplis VA, Castellino FJ.

Physiol Genomics. 2003 Nov 11;15(3):228-35.

PMID:
13130079
17.

The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis.

Li Q, Ishikawa TO, Oshima M, Taketo MM.

Cancer Res. 2005 Oct 1;65(19):8622-7.

18.

Myh deficiency enhances intestinal tumorigenesis in multiple intestinal neoplasia (ApcMin/+) mice.

Sieber OM, Howarth KM, Thirlwell C, Rowan A, Mandir N, Goodlad RA, Gilkar A, Spencer-Dene B, Stamp G, Johnson V, Silver A, Yang H, Miller JH, Ilyas M, Tomlinson IP.

Cancer Res. 2004 Dec 15;64(24):8876-81.

19.

Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity.

Li P, Schulz S, Bombonati A, Palazzo JP, Hyslop TM, Xu Y, Baran AA, Siracusa LD, Pitari GM, Waldman SA.

Gastroenterology. 2007 Aug;133(2):599-607. Epub 2007 Jun 2.

PMID:
17681179
20.

Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells.

Aoki K, Aoki M, Sugai M, Harada N, Miyoshi H, Tsukamoto T, Mizoshita T, Tatematsu M, Seno H, Chiba T, Oshima M, Hsieh CL, Taketo MM.

Oncogene. 2007 May 24;26(24):3511-20. Epub 2006 Dec 11.

PMID:
17160019

Supplemental Content

Support Center